Biosurgery Market

Report ID: GMI3807
Download Free PDF
Summary
Methodology

Biosurgery Market Size

The global biosurgery market size will grow considerably from 2025 to 2034, driven by the increasing need for sophisticated surgical procedures and the overall transition towards minimally invasive surgeries. The burden of chronic disease, along with the growing aging population, is anticipated to fuel the usage of biosurgery products in several therapeutic indications.

Based on the World Health Organization (WHO), one person in six worldwide will be 60 years and older by 2030. By 2050, the number of people 60 years and older is estimated to double, totaling 2.1 billion. The population aged 80 and above is estimated to triple between 2020 and 2050, reaching 426 million. This demographic transition is also expected to boost the number of surgical procedures, thus making biosurgery solutions stronger in terms of market outlook.

Together with demographic and epidemiological patterns, technological innovations in surgical instruments, hemostats, and regenerative materials are rewriting the rules of surgical practice. As healthcare systems around the world strive to improve surgical outcomes and minimize postoperative complications, biosurgery products are increasingly being adopted for their proven ability to enhance hemostasis, tissue sealing, and wound healing.

The biosurgery market is also being supported by the growing incidence of lifestyle disorders, including obesity, diabetes, and cardiovascular disease, that often necessitate surgical intervention. In addition, the rising incidence of orthopedic surgeries, organ transplants, and oncological surgeries is widening the use of biosurgical products. The quick growth of the healthcare infrastructure, especially in emerging economies, as well as the rising popularity of medical tourism, is providing great opportunities for growth to industry players.

With the increasing number of surgical procedures, the demand for successful biosurgery solutions to maximize clinical outcomes is on the rise as well. Additionally, increased emphasis on patient-centric care, growing healthcare awareness, and expanding disposable incomes in emerging markets are favorably positioning the market.

Biosurgery Market Trends

One of the strongest trends in the marketplace is the rising use of minimally invasive procedures (MIS) with the help of advancements in laparoscopic and robotic-assisted surgery. MIS procedures provide advantages like minimal blood loss, shorter stays in hospitals, and rapid recovery. Biosurgery products such as absorbable hemostats, sealants, and adhesives are seeing higher usage in MIS procedures.

Another key trend is the growing convergence of biotechnology and biomaterials in the creation of biosurgical products. Firms are making active investments in R&D to develop more durable, biocompatible, and effective materials that can promote tissue regeneration and minimize the immune response risk. This innovation-centric strategy is transforming the market, allowing for wider clinical application and better patient outcomes.

In addition, the increasing trend towards personalized medicine also impacts biosurgery strategies. Personalized surgical strategies and patient-specific implants are increasingly popular, which in turn require biosurgery products that are compatible with individualized treatment strategies. Furthermore, the spike in sports injuries and trauma cases is driving the demand for biosurgical products in orthopedic and emergency departments.

Biosurgery Market Analysis

The hemostatic agents market is expected to exhibit appreciable growth during the forecast period due to the growing rates of surgical procedures, trauma, and bleeding complications. Hemostats play a critical role in stopping bleeding in surgeries and are commonly used in many specialties like general surgery, orthopedics, neurosurgery, and cardiovascular surgery.

Development in formulation, ease of application, and absorption rates is improving the clinical value of hemostatic agents. Continued R&D activities are aimed at enhancing the safety and efficacy value of these products, leading to greater adoption rates. For example, companies are now formulating combination hemostats that combine mechanical and biologically active ingredients for improved performance.

The cardiovascular surgery market is anticipated to record a high CAGR during the forecast period from 2025 to 2034. This is mainly due to the rising global prevalence of cardiovascular diseases (CVDs), the leading cause of death globally. Biosurgical devices play an important part in cardiovascular operations by providing effective hemostasis, sealing of vascular grafts, and tissue regeneration. The presence of advanced surgical equipment and methods is further propelling the use of biosurgery in complicated cardiac operations.

Region-wise, the North America biosurgery market is set to continue its dominance in the forecast period, thanks to the high level of healthcare infrastructure in the region, the high level of spending on healthcare, and the strong R&D environment. The availability of major market players and early incorporation of new technologies also support the dominance of the region.

Moreover, supportive reimbursement structures and greater awareness among healthcare providers regarding the value proposition of biosurgery products are propelling product uptake in the U.S. and Canada. Additionally, the growing volume of elective procedures, combined with government efforts to enhance patient outcomes, is likely to further market growth in the region.

Asia Pacific is also becoming an attractive biosurgery market, driven by aggressive urbanization, increasing healthcare expenditure, and an expanding middle-class population with enhanced access to surgical facilities. China, India, and South Korea are experiencing booming surgical procedures, thus generating high demand for biosurgical solutions.

Biosurgery Market Share

The biosurgery industry's competitive landscape is dominated by both stalwarts and startups dealing in surgical innovation.

Major players are:

  • Johnson & Johnson
  • Baxter
  • C.R. Bard
  • BD
  • Stryker Corporation
  • Pfizer and Medtronic.

These companies are intensely investing in R&D to launch differentiated offerings and become competitive players. Strategic alliances, mergers & acquisitions, and expansion across geographies are prevalent strategies undertaken by these players to reinforce their market outreach.

Startups and mid-sized firms are adding to the competitive forces by offering niche and customized biosurgery solutions specific to particular clinical requirements. These new entrants are utilizing advanced technologies like 3D printing, nanotechnology, and bioresorbable materials to provide next-generation surgical solutions.

Biosurgery Industry News

  • In June 2025, Dilon Technologies, a leading medical device company with a specialty in biosurgery and breast cancer treatment, raised $9 million in growth capital from JGB Management. The funding is intended to accelerate Dilon's double-digit growth rate and improve its operational scalability.

 

Author: Mariam Faizullabhoy ,

Related Reports

Pre Book Now

Download Free Sample